Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, with reference to paragraph 10 of NHS England's board paper, Allocation of resources to NHS England and the commissioning sector for 2016/17 to 2020/21, reference PB.17.12.15/04, if he will quantify the legally binding funding pressures regarding the introduction of treatments for (a) hepatitis C and (b) cystic fibrosis in 2016-17; and if he will make a statement.

NHS England has estimated a range for the impact of implementing planned and published National Institute for Health and Care Excellence Guidance relating to treatments for hepatitis C and cystic fibrosis. Due to the commercial in confidence agreements in place a specific figure cannot be provided at this time.